Davide Leone & Partners Investment Company’s BioMarin Pharmaceuticals BMRN Stock Holding History

Davide Leone & Partners Investment Company’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-715,370	Closed	-$55.3M	–	11
2021 Q3	$55.3M	Sell	715,370 -239,084	-25%	-$18.9M	4.23%	4
2021 Q2	$79.6M	Sell	954,454 -10,215	-1%	-$810K	3.82%	5
2021 Q1	$72.8M	Buy	964,669 +60,264	+7%	+$4.92M	9.08%	3
2020 Q4	$79.3M	Hold	904,405	–	–	8.26%	3
2020 Q3	$68.8M	Buy	+904,405	New	+$91.5M	7.8%	5

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Davide Leone & Partners Investment Company's BMRN Position: Q4 2021 in Review

Davide Leone & Partners Investment Company sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2021, closing a stake of 715,370 shares — an estimated $55.3M sold.

Davide Leone & Partners Investment Company first reported a position in BMRN in Q3 2020 and held it in 5 quarters. The position peaked at $79.6M in Q2 2021. 557 funds tracked by Wall St. Rank hold BMRN as of Q4 2021.

Davide Leone & Partners Investment Company reported no remaining BioMarin Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Davide Leone & Partners Investment Company sold 715,370 BioMarin Pharmaceuticals shares in Q4 2021, an estimated $55.3M.
Davide Leone & Partners Investment Company first reported a position in BioMarin Pharmaceuticals in Q3 2020 and held it in 5 quarters.
Davide Leone & Partners Investment Company's BioMarin Pharmaceuticals position peaked at $79.6M in Q2 2021.
557 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2021.

Based on Davide Leone & Partners Investment Company's 13F filing for Q4 2021, filed 14 Feb 2022.